Fusion Pharmaceuticals Inc. - FORM S-1 - EX-23.1 - June 5, 2020

Attached files

file filename
EX-21.1 - EX-21.1 - Fusion Pharmaceuticals Inc.d872512dex211.htm
EX-16.1 - EX-16.1 - Fusion Pharmaceuticals Inc.d872512dex161.htm
EX-10.17 - EX-10.17 - Fusion Pharmaceuticals Inc.d872512dex1017.htm
EX-10.16 - EX-10.16 - Fusion Pharmaceuticals Inc.d872512dex1016.htm
EX-10.15 - EX-10.15 - Fusion Pharmaceuticals Inc.d872512dex1015.htm
EX-10.14 - EX-10.14 - Fusion Pharmaceuticals Inc.d872512dex1014.htm
EX-10.13 - EX-10.13 - Fusion Pharmaceuticals Inc.d872512dex1013.htm
EX-10.12 - EX-10.12 - Fusion Pharmaceuticals Inc.d872512dex1012.htm
EX-10.11 - EX-10.11 - Fusion Pharmaceuticals Inc.d872512dex1011.htm
EX-10.1 - EX-10.1 - Fusion Pharmaceuticals Inc.d872512dex101.htm
EX-4.4 - EX-4.4 - Fusion Pharmaceuticals Inc.d872512dex44.htm
EX-4.3 - EX-4.3 - Fusion Pharmaceuticals Inc.d872512dex43.htm
EX-4.1 - EX-4.1 - Fusion Pharmaceuticals Inc.d872512dex41.htm
EX-3.4 - EX-3.4 - Fusion Pharmaceuticals Inc.d872512dex34.htm
EX-3.1 - EX-3.1 - Fusion Pharmaceuticals Inc.d872512dex31.htm
S-1 - S-1 - Fusion Pharmaceuticals Inc.d872512ds1.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the use in this Registration Statement on Form S-1 of Fusion Pharmaceuticals Inc. of our report dated April 3, 2020, except with respect to the matters that have removed the substantial doubt about the Company’s ability to continue as a going concern discussed in Note 1, as to which the date is June 5, 2020, relating to the financial statements of Fusion Pharmaceuticals Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

June 5, 2020

Fusion Pharmaceuticals Inc. Reports